These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
813 related articles for article (PubMed ID: 9699127)
1. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma. Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127 [TBL] [Abstract][Full Text] [Related]
2. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma]. Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438 [TBL] [Abstract][Full Text] [Related]
3. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)". Fink M; Weinhüsel A; Niederle B; Haas OA Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874 [TBL] [Abstract][Full Text] [Related]
4. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas. Komminoth P Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671 [TBL] [Abstract][Full Text] [Related]
5. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404 [TBL] [Abstract][Full Text] [Related]
6. RET oncogene mutations in medullary thyroid carcinoma in Mexican families. González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374 [TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A. Landsvater RM; Jansen RP; Hofstra RM; Buys CH; Lips CJ; Ploos van Amstel HK Hum Genet; 1996 Jan; 97(1):11-4. PubMed ID: 8557249 [TBL] [Abstract][Full Text] [Related]
8. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299 [TBL] [Abstract][Full Text] [Related]
9. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas. Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130 [TBL] [Abstract][Full Text] [Related]
10. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ; Mulligan LM; Eng C Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949 [TBL] [Abstract][Full Text] [Related]
11. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218 [TBL] [Abstract][Full Text] [Related]
12. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers]. Sansó G; Domené HM; Iorcansky S; Barontini M Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252 [TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma. Shirahama S; Ogura K; Takami H; Ito K; Tohsen T; Miyauchi A; Nakamura Y J Hum Genet; 1998; 43(2):101-6. PubMed ID: 9621513 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations. Kambouris M; Jackson CE; Feldman GL Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338 [TBL] [Abstract][Full Text] [Related]
15. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111 [TBL] [Abstract][Full Text] [Related]
16. [Proto-oncogene RET somatic mutations in medullary thyroid carcinoma]. Wiench M; Kwaśniewski M; Gubała E; Wygoda Z; Pawlaczek A; Oczko M; Jarzab B Wiad Lek; 2001; 54 Suppl 1():415-21. PubMed ID: 12182058 [TBL] [Abstract][Full Text] [Related]
17. A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. Berndt I; Reuter M; Saller B; Frank-Raue K; Groth P; Grussendorf M; Raue F; Ritter MM; Höppner W J Clin Endocrinol Metab; 1998 Mar; 83(3):770-4. PubMed ID: 9506724 [TBL] [Abstract][Full Text] [Related]
18. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma. Frilling A; Dralle H; Eng C; Raue F; Broelsch CE Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529 [TBL] [Abstract][Full Text] [Related]
19. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A. Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376 [TBL] [Abstract][Full Text] [Related]
20. RET proto-oncogene mutations in French MEN 2A and FMTC families. Schuffenecker I; Billaud M; Calender A; Chambe B; Ginet N; Calmettes C; Modigliani E; Lenoir GM Hum Mol Genet; 1994 Nov; 3(11):1939-43. PubMed ID: 7874109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]